Welcome to our dedicated page for Sana Biotechnology SEC filings (Ticker: SANA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sana Biotechnology, Inc. (NASDAQ: SANA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sana’s common stock is registered on The Nasdaq Global Select Market under the symbol SANA, and its filings offer detailed information on financial performance, capital markets activity, and progress in its engineered cell programs.
Investors can review current reports on Form 8-K in which Sana furnishes quarterly financial results, discusses non-GAAP measures, and describes material events such as equity offerings, impairment charges related to facilities, and portfolio prioritization decisions. These filings also summarize clinical and preclinical updates for programs like UP421, SC451, and in vivo CAR T candidates built on the fusogen platform, as well as interactions with regulators and key scientific publications.
Other SEC documents, including registration statements and prospectus supplements referenced in Sana’s 8-K filings, outline the terms of public offerings of common stock and pre-funded warrants, at-the-market sales programs, and related underwriting agreements. Governance-related 8-K items describe changes in board composition and senior leadership roles, with explanations of director resignations and executive transitions.
On Stock Titan, Sana’s filings are paired with AI-powered summaries that help explain the significance of each document, from quarterly results to material agreements. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while specialized views make it easier to identify items related to financing transactions, clinical disclosures, and corporate governance. This structure allows users to navigate Sana’s regulatory history and better understand how its engineered cell and gene therapy initiatives are reflected in official SEC reports.
Sana Biotechnology, Inc. executive vice president and chief scientific officer Dhavalkumar Dhirajlal Patel filed an initial ownership report showing his equity interests in the company. The filing lists stock options to purchase 515,000, 375,000, and 506,250 shares of common stock at exercise prices of $5.84, $2.55, and $3.41 per share, with expirations in 2034, 2035, and 2036. It also discloses restricted stock units covering 375,000, 62,500, and 112,500 shares, each RSU representing a contingent right to one share of common stock, along with 99,510 shares of common stock held directly. Footnotes describe standard time-based vesting schedules that require continuous service to Sana.
Sana Biotechnology President & CEO Steve Harr reported routine equity compensation activity. On March 6 and 7, 2026, he exercised restricted stock units to acquire a total of 91,666 shares of common stock at $0.00 per share. Related to these vestings, on March 9, 2026, 11,526 shares and 12,819 shares of common stock were disposed of at approximately $3.13 and $3.10 per share, respectively, to satisfy tax liabilities. Following these transactions, Harr directly holds 7,944,251 shares of Sana common stock, with additional indirect holdings reported through family trusts. Footnotes explain that the RSU awards vest over several years, contingent on Harr’s continued service with Sana.
Sana Biotechnology, Inc. officer Susan D. Wyrick exercised restricted stock units into common stock and had shares withheld to cover taxes. On March 6–7, she converted a total of 13,666 restricted stock units into the same number of common shares at a stated price of $0.00. On March 9, 4,387 common shares were disposed of at about $3.11 per share as tax-withholding transactions, not open-market sales. After these moves, she directly held 196,196 common shares, with additional restricted stock units scheduled to vest over several years, subject to continued service.
Sana Biotechnology, Inc. reported that officer Susan D. Wyrick acquired new equity awards. She received 45,833 restricted stock units and a stock option for 206,250 shares on March 5, 2026, both at a grant price of $0.00 per unit or option.
The restricted stock units vest in four equal installments on March 5 of 2027, 2028, 2029 and 2030, conditioned on continued service with Sana. The stock option vests as to 25% of the underlying shares on March 5, 2027 and then in 36 equal monthly installments, also requiring continuous service.
Sana Biotechnology President & CEO Steve Harr received new equity awards. On March 5, he was granted 200,000 restricted stock units and stock options for 900,000 shares of Sana common stock, both at a per-share exercise price of $0.00.
The 200,000 restricted stock units each represent a right to receive one share of Sana common stock and vest in four equal installments on March 5 of 2027, 2028, 2029 and 2030, if he continues to serve the company. The 900,000-share stock option vests as to 25% of the underlying shares on March 5, 2027, then in 36 equal monthly installments thereafter, also conditioned on continued service.
Sana Biotechnology, Inc. officer Susan D. Wyrick reported equity transactions involving restricted stock units and common shares. On March 2, 2026, 1,525 restricted stock units were exercised into 1,525 shares of common stock at $0.00 per share, increasing her direct holdings to 187,408 common shares. On March 3, 2026, 491 common shares were disposed of at $3.91 per share to satisfy tax withholding obligations, leaving 186,917 common shares directly owned. Each restricted stock unit represents a right to receive one share of Sana common stock, vesting in four annual 25% installments on March 2 of 2024, 2025, 2026 and 2027, subject to continued service.
Sana Biotechnology, Inc. filed a shelf registration and prospectus supplement to offer up to $150,000,000 of common stock under an at-the-market sales agreement with TD Securities (USA) LLC (TD Cowen), with sales to occur from time to time after the effective date.
The registration statement also carries forward $216,385,563 of Unsold Securities from a prior Form S-3 (File No. 333-277584) pursuant to Rule 415(a)(6). Shares outstanding were 266,731,648 as of December 31, 2025, used as the reference base for share counts in the supplement.
Sana Biotechnology, Inc. provides an in-depth annual overview of its high-risk cell and gene engineering business, focused on treating diseases at their root cause with engineered cells. The company highlights substantial doubt about its ability to continue as a going concern and a need for additional funding to finance operations.
Sana’s lead ex vivo program, SC451, is a hypoimmune iPSC-derived pancreatic islet cell therapy aimed at type 1 diabetes, a condition affecting almost ten million people worldwide. First-in-human data with related product UP421 show HIP-modified allogeneic islet cells surviving and functioning 12 months without immunosuppression, with C‑peptide production and imaging evidence of graft survival.
Its lead in vivo program, SG293, uses a CD8-targeted fusogen to generate CD19 CAR T cells inside the body for B cell cancers and B cell mediated autoimmune diseases, supported by non‑human primate data showing robust CAR T generation and deep B cell depletion without lymphodepletion. The company has suspended other allogeneic CAR T trials to concentrate resources on SC451 and SG293, emphasizing significant scientific potential but heavy dependence on future clinical success, regulatory approvals, and new capital.
Sana Biotechnology entered an amended at-the-market sales agreement that will support a new Form S-3 registration for up to $150.0 million of common stock, with TD Cowen as sales agent earning up to 3.0% of gross proceeds.
The company reported 2025 cash, cash equivalents, and marketable securities of $138.4 million and expects its cash runway to extend into late 2026. GAAP net loss was $244.2 million for 2025, improved from $266.8 million in 2024, with non-GAAP net loss of $170.1 million. Research and development and general and administrative expenses declined meaningfully after a 2024 portfolio prioritization, partly offset by a $44.6 million impairment tied to reduced internal manufacturing build-out.
Operationally, Sana highlighted encouraging type 1 diabetes data from UP421, progress toward an IND for SC451, and advancement of in vivo CAR T candidate SG293, along with appointments including a new Chief Financial Officer and total 2025 equity gross proceeds of $133.7 million.
Piper Brian reported acquisition or exercise transactions in this Form 4 filing.
Sana Biotechnology, Inc. reported that EVP and Chief Financial Officer Brian Piper received new equity awards. He was granted 200,000 restricted stock units, each representing a right to receive one share of common stock, and a stock option for 900,000 shares.
The restricted stock units vest in four equal installments on February 17 of 2027, 2028, 2029 and 2030, if he continues providing service through each date. The stock option vests as to 25% of the shares on February 17, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, also subject to continued service.